Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp., a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It also provides DNlite test, a series of patented and clinically validated non-invasive urine test for monitoring the progression of diabetic nephropathy, including … Read more
Bio Preventive Medicine Corp. (6810) - Total Liabilities
Latest total liabilities as of June 2025: NT$115.46 Million TWD
Based on the latest financial reports, Bio Preventive Medicine Corp. (6810) has total liabilities worth NT$115.46 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bio Preventive Medicine Corp. - Total Liabilities Trend (2020–2024)
This chart illustrates how Bio Preventive Medicine Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bio Preventive Medicine Corp. Competitors by Total Liabilities
The table below lists competitors of Bio Preventive Medicine Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Perk International Inc
PINK:PRKI
|
USA | $318.06K |
|
CHINA COMM SRVCS-H
MU:CMW
|
Germany | €78.12 Billion |
|
ORION ENRGY SYS
BE:5A4
|
Germany | €40.68 Million |
|
ICDS Limited
NSE:ICDSLTD
|
India | ₹30.86 Million |
|
Bera Holding AS
IS:BERA
|
Turkey | TL8.17 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Bio Preventive Medicine Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bio Preventive Medicine Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bio Preventive Medicine Corp. (2020–2024)
The table below shows the annual total liabilities of Bio Preventive Medicine Corp. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$122.61 Million | -1.69% |
| 2023-12-31 | NT$124.73 Million | -5.92% |
| 2022-12-31 | NT$132.58 Million | +789.90% |
| 2021-12-31 | NT$14.90 Million | -24.40% |
| 2020-12-31 | NT$19.71 Million | -- |